Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.
US-based kidney disease treatment developer Walden Biosciences launched on Tuesday with $51m it secured in a series A round to advance research conducted by faculty at Rush and Harvard universities.
The round was co-led by pharmaceutical company UCB’s corporate venturing fund, UCB Ventures, and venture capital firm Arch Venture Partners.
Founded earlier this year, Walden is working on therapeutics designed to restore renal function in the body by targeting cells specific to the kidney and its biologic processes,…
